In pancreatic cancer, mutant Kras drives release of CXCL1, 2 and 5, which are CXCR2 ligands necessary for angiogenesis, myeloid cell infiltration and tumor progression (O'Hayer et al., 2009; Li et al., 2011). This evidence concerns the gene KRAS and neoplasm.